aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2021 Financial Results
aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.
- aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.
- aTyrs research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases.
- aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets.
- aTyrs primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases.